SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Zura Bio Ltd - Ordinary Shares - Class A

Zura Bio is seeing increased trading activity following a public offering of Class A Ordinary Shares that has tightened supply and stabilized its price action. Investors are closely monitoring the stock for a potential momentum push as they look past the recent dilution toward upcoming Phase 2 clinical trial readouts for its lead autoimmune drug, Tibulizumab.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is facing significant market pressure as investors digest conservative long-term revenue guidance and the looming expiration of the TDAPA reimbursement period, despite ongoing share buybacks and institutional accumulation. The community is sharply divided, with some actively debating the long-term potential of the DefenCath product line and Rezzayo clinical trial results, while others express frustration over management's communication and the stock's persistent volatility.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a massive fourth-quarter earnings beat, where revenue growth and a shift to profitability fueled significant investor optimism. The community is buzzing with speculation about a potential buyout as the company clears its balance sheet, while simultaneously tracking key catalysts like pending EU regulatory decisions and patent extensions.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is seeing intense investor focus as rising geopolitical tensions in the Middle East and concerns over European natural gas supply drive demand for energy-related plays. Traders are closely monitoring a potential short squeeze, citing an extremely high cost to borrow and a limited float, while the community actively debates whether the stock's recent momentum will lead to a breakout into double digits.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as investors react to a significant binding agreement with Yotta Data Services to deploy high-performance GPU infrastructure in India, sparking intense debate over whether the company’s pipeline and recent contract wins finally justify its current valuation. While the community is split between bullish sentiment regarding the company’s growth potential and skepticism over transparency, communication strategies, and the pace of execution, the stock remains a focal point for traders tracking potential short squeeze dynamics due to its compressed price and tight float.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is garnering attention as the essential data backbone for institutional finance, with the community closely tracking its integration into major market infrastructure. While price action remains a point of contention among traders, discussion is heavily focused on the protocol's long-term utility in enabling real-world asset tokenization and the potential for a regulatory breakthrough to catalyze its next growth phase.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting strong Week 40 Phase 3 VELA clinical trial results, which investors view as validation of the drug's best-in-class potential for treating hidradenitis suppurativa. The community is actively discussing the stock's significant upside potential, fueled by anticipation of upcoming trial readouts and ongoing speculation surrounding potential M&A activity.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors debate a proposed major executive compensation package, with community sentiment deeply divided between calls for a proxy management vote and optimism regarding potential future M&A activity. The discussion is further fueled by persistent technical debates over short interest data, long-term share accumulation strategies, and technical analysis of the stock's recent price consolidation.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is trending as market participants weigh strong quarterly earnings and AUM growth against ongoing volatility in the private credit sector and recent concerns over interest rate sensitivity. The community remains focused on the firm's strategic expansion into sports and infrastructure, while actively debating the broader sustainability of the private equity business model in the current high-rate environment.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is experiencing significant volatility as investors weigh robust quarterly results and a massive revenue surge against conservative forward guidance. While the community is actively debating whether the recent dip represents an overreaction by algorithms or legitimate valuation concerns, many are focusing on the company's long-term potential as a critical player in AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardiol Therapeutics (TSE:CRDL) Trading Up 10.5% - Time to Buy?

Cardiol Therapeutics (TSE:CRDL) Trading Up 10.5% - Still a Buy...

Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday

Cardiol Therapeutics (NASDAQ:CRDL) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-1-cardiol-therapeutics-inc-stock-1...

Cardiol Therapeutics (TSE:CRDL)  Shares Down 1.5%   - Time to Sell?

Cardiol Therapeutics (TSE:CRDL) Stock Price Down 1.5% - Here's What Happened...

Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference

Cardiol Therapeutics (NASDAQ:CRDL) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its clinical development programs targeting inflammation in cardiac disease, with its...

Cardiol Therapeutics (NASDAQ:CRDL) Shares Down 1% - What's Next?

Cardiol Therapeutics (NASDAQ:CRDL) Stock Price Down 1% - Here's Why...

Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?

PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.

Cardiol Therapeutics (TSE:CRDL) Trading Down 4.8% - Time to Sell?

Cardiol Therapeutics (TSE:CRDL) Shares Down 4.8% - What's Next...

Equities Analysts Set Expectations for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Research analysts at Brookline Cap M issued their FY2025 EPS estimates for shares of Cardiol Therapeutics in a note issued to investors on...

Cardiol Therapeutics (NASDAQ:CRDL) Stock Rating Upgraded by Brookline Cap M

Brookline Cap M upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a research report on Tuesday...

Analysts Offer Predictions for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at Brookline Capital Management issued their FY2025 earnings per share estimates for Cardiol Therapeutics in a research report...

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc - Ordinary Shares - Class A

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.08	--	--	N/A
Q3 '25	-$0.08	-$0.09	-2.94%	MISSED
Q2 '25	-$0.09	-$0.07	18.86%	BEAT
Q1 '25	-$0.08	-$0.07	13.37%	BEAT
Q4 '24	-$0.09	--	--	N/A

CRDL
Cardiol Therapeutics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest CRDL News

CRDLCardiol Therapeutics Inc - Ordinary Shares - Class A